XNAS
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.
NovaBridge’s first-half loss widened to **$0.33/share** versus **$0.14** expected, a weak result with no offsetting revenue disclosure or clear catalyst. With no recent news and no visible growth inflection, execution looks poor and the stock deserves caution.
AI-generated summary — powered by BigEarnings.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-20 | H1 2026 | -0.14 | -0.33 | -135.71% | $0 | ❌ Miss | +1.01% | -1.05% | — |
| 2026-04-07 | FY 2025 | -0.22 | -0.21 | +4.55% | $0 | ✅ Beat | +3.23% | +2.42% | -10.48% |
Showing last 2 quarters.